Louisville Business First: The is the second time in about 18 months that this company has turned heads with its capital raises. FULL STORY
On September 17, 2020, Talaris was awarded the 2020 Citeline Award for Clinical Trial Result of the Year. This award recognizes the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare. The judges sought to recognize the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design.
The 2020 Citeline Awards (previously CARE Awards) were created to recognize myriad accomplishments across the biopharmaceutical industry, providing an opportunity for the industry to honor its highest achievers. Achievements across the spectrum of key R&D activities are celebrated, from successes in early and late-stage research, to advances in technological tools, to innovations in trial design and execution.
The Citeline Awards gather distinguished leaders in the biopharmaceutical, CRO, and diagnostic industries from all corners of the globe. To learn more, visit:
Louisville Business First: The Louisville-based biotech could see it gamechanging treatment expand to many more people in need an organ transplant. »FULL STORY
SpectrumNews1: LOUISVILLE, Ky. — Robert Waddell is a kidney recipient, but he hasn’t taken immunosuppressants for 10 years. It’s because he decided to opt into a cell therapy clinical trial when polycystic kidney disease forced him into needing a transplant. »FULL STORY
Talaris Therapeutics plans to initiate a Phase 1/2a trial to test its investigational cell therapy, FCR001, in people with diffuse cutaneous systemic sclerosis (dcSSc), the company has announced.
The trial follows the recent approval of an investigational new drug application for FCR001 by the U.S. Food and Drug Administration (FDA), and will be conducted across multiple sites in the U.S., including at Duke University and the University of Michigan. » FULL STORY
The high-potential Louisville-based biotech is expanding its study of what kinds of diseases its signature treatment could resolve with a new clearance from the FDA.
Louisville Business First FULL STORY
Members of the Louisville business community gathered Tuesday night to recognize and celebrate 31 health care professionals at Louisville Business First’s 2020 Health Care Heroes banquet.
Scott Requadt, CEO of Talaris Therapeutics Inc., headlined the event with a keynote address and question-and-answer session with LBF Editor Shea Van Hoy before a sell-out crowd of about 240 attendees at the Galt House.
Photo: Christopher Fryer/Louisville Business First
KidneyNews features the Talaris approach and FREEDOM-1 Study
“This study is the most exciting development to date in the field of immunologic tolerance induction and, if successful, will represent a paradigm shift in the practice of organ transplantation.”
Louisville Business First features Scott Requadt in their 20 People to Know in Healthcare: FULL STORY
Talaris is honored to be named a life science startup to watch by BioSpace. 2020 is a big year for us as we expand our Phase 3 trial to enroll patients undergoing living donor kidney transplants at sites across the country.